Article Sidebar
Views pdf: 117
FIRST-LINE TREATMENT OUTCOMES FOR STAGE IV LUNG CANCER WITH EGFR MUTATIONS USING ERLOTINIB AT THANH NHAN HOSPITAL
Main Article Content
Abstract
Objectives: Evaluate the first-line treatment outcomes for stage IV lung cancer with EGFR gene mutations using Erlotinib at Thanh Nhan Hospital. Methods: Retrospective description with longitudinal follow-up, 51 patients diagnosed with stage IV non-small cell lung cancer with EGFR mutations were treated with Erlotinib from January 2018 to May 2025 at Thanh Nhan Hospital. Result: The average age was 66.8 ± 10.4 years. The female-to-male ratio was 1.1:1. Among the patients, 78.5% achieved partial response, and 7.8% showed disease progression. The disease control rate was 92.2%. The median progression-free survival (PFS) was 12 months, with a range from 4 months to 37 months. The PFS at the 1-year mark was 46.6%. Conclusions: First-line treatment with Erlotinib yields a high treatment response and few side effects.
Article Details
Keywords
Lung cancer, EGFR, first-line Erlotinib
References
2. Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA oncology. 2021; 7(12):1824-1832.
3. Castellanos E, Feld E, Horn L. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(4):612-623.
4. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012;13(3):239-246.
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. 2011;12(8):735-742.
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
7. Mai Trọng Khoa, Ngô Thùy Trang, Nguyễn Thị Lan Anh, CS v. Nghiên cứu tiến cứu, dịch tễ học phân tử, đánh giá tình trạng đột biến gen EGFR ở các BN Việt Nam mắc UTP dạng biểu mô tuyến, giai đoạn tiến triển. Tạp chí Ung thư học Việt Nam. 2016: 2/2016, 2030-2036.
8. Lê Thu Hà, Trần Văn Thuấn (2016). Đáp ứng thuốc erlotinib trong điều trị bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn. Tạp chí Y học thực hành, số 993, tháng 1- năm 2016, trang 53-55.
9. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-162.